NH Hospital's innovative approach to mental health is based on the patient's biochemical makeup and gene-environment interfaces. Photo courtesy of NH Hospital

There's no one-size-fits-all solution to medical care. NH Hospital is bringing innovative technologies and functional medicine to patients in the Houston area. Using patients' biochemical makeup, the medical provider has created a unique service for Houstonians seeking a multi-pronged approach to behavioral health and substance use disorders.

The past year has been an incubator for mental health issues. Pandemic isolation, social distancing, financial instability, racial reckonings, and a massive death toll have posed an enormous threat to the mental wellbeing of people around the world. Experts predict a long-term spike in post-traumatic stress disorder (PTSD) cases as society grapples with the tragedies of the last year, but the toll is already here.

A recent Centers for Disease Control and Prevention (CDC) study found that the percentage of adults with recent symptoms of anxiety or depression increased from 36.4 to 41.5 percent between Aug. 19, 2020, and Feb. 1, 2021.

As the world waits for a moment to exhale after a catastrophic year, NH Hospital keeps busy serving patients struggling with both behavioral health and addiction during the pandemic. Outside of depression and anxiety, the facility also treats bipolar disorder, PTSD, codependency, and postpartum depression by using a multidisciplinary approach.

NH Hospital integrates traditional medicine with functional medicine with a mission of treating the root cause of an issue and not just the symptoms. From providing an on-site chef and nutritionist to stimulating patients with calming acoustic therapy, the facility blends unique treatment modalities that address the whole body rather than an isolated issue.

"With functional medicine, we find other avenues and ways to allow [patients] to heal and to change their behavior," explains Debbie Cormier, CEO of NH Hospital.

Using genetic markers as a roadmap to health

You can build the closet of Carrie Bradshaw's dreams online, buy bespoke cologne based on your body chemistry, monogram jewelry and clothing, and even get a Renaissance-style portrait of your family pet. Tailor-made options are ubiquitous; why not customize medical care?

"For years, the traditional way, we just gave people the same amount of meds, the same diets, the same everything," and wondered why some patients responded better or quicker than others, explains Cormier. For the unlucky patients who didn't get stellar results, she says doctors may have thought "they just have to deal with it" and wait. "We don't feel that you should have to just deal with it," she continues.

When treating a patient, NH Hospital doctors consider the genetic makeup of each patient to create a custom care plan. With tests as simple as a swab of the cheek, the facility can gather biochemical markers that can share valuable medical information like risk factors for diseases.

Cormier believes NH Hospital's ability to look at a patient's genetic background and "treat you as an individual," is a key factor that sets the facility apart. The hospital also focuses on understanding how your genes interact with your environment.

Think of gene-environment interactions as nature vs. nurture, an ideology that research suggests plays significant roles in the outset of mental illness. Genetic and environmental factors interact to influence phenotype, the observable characteristics you exhibit when your genotype and environment interact.

When these factors are off-balance, it can result in undesirable results. A 2001 study of Finnish twins studied the socio-geographic impact on adolescent alcohol use in urban and rural environments. While the frequency of alcohol use was the same in both settings, the factors that led adolescents to drink were entirely different. Genetic factors played a larger role in urban areas, whereas the shared environment had a greater influence in rural settings.

By applying various modalities based on genetic information, doctors aren't going in blind and "know you from the inside out," says Cormier.

When a patient comes in struggling with something as grappling as depression or anxiety, conditions they've seen an uptick in since the beginning of the pandemic, doctors will run a genetic test as well as traditional lab work. Cormier says some potential treatment paths may include photosynthesis therapy, hydration therapy and nutrition.

Dietetics meets tech

NH Hospital helps patients get micronutrient infusions, but its nutrition program provides an integrated approach to fueling the body with the help of a staff chef.

"We only have so much energy every day, and we choose how we use the energy but by getting your diet right, it starts to heal you in all kinds of ways," says Cormier.

While the physical repercussions of a poor diet like diabetes and heart disease are widely known, you may be surprised to hear that nutrition can affect mood disorders and harm brain cells. According to Harvard Health Publishing, refined sugars can lead to brain impairment, depression and oxidative stress — the free radicals produced when the body uses oxygen, which can damage cells. By focusing on a patient's nutrition, "the person has a better chance to heal, not only from the issue that is brought to us but to overall feel good," she says.

Counseling, cryotherapy, transcranial magnetic stimulation and cocoon therapy therapies are just some of the other methods NH Hospital doctors use to treat their patients.

Cormier recalls the recovery of a patient who was experiencing depression and using a wheelchair due to pain in her knees. She gradually gained the ability to walk without pain again after a months-long treatment plan of cryotherapy and micronutrient infusions.

"She said that we really changed her life because we gave her back her life. Now she's walking a mile a day around her block and she's able to do daily moving. She said she hadn't done that in years," says Cormier.

A mission to heal

Outside of neuropsychology, NH Hospital offers medical detox with monitoring from trained professionals and therapy plans for patients coming off of alcohol, methamphetamine, heroin, opioids like fentanyl and other prescription drugs.

Since the U.S. The Department of Health and Human Services declared the opioid epidemic as a public health emergency in 2017, nearly 841,000 people have died of an opioid overdose. Like anxiety and depression, addiction is also on the rise during the pandemic. A CDC survey found that 13 percent of respondents began using drugs during the pandemic or increased their use of illicit substances.

NH Hospital doctors provide micronutrients among other aides to help "build [patients] up] before taking them off the drugs, says Cormier. "We're just trying to make sure the patient feels safe and that if we're doing all these things, we continue to move them in a positive direction instead of just letting them sweat it out," she says.

"Our leadership here is committed to doing what it takes to help people whether they have behavioral, medical, or whatever [condition] brings them through our doors so that we make them have a better life," says Cormier.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

These 5 trailblazing Houston startups are leading the energy transition

meet the finalists

Houston is home to a growing number of startups reshaping what it means to be called the "Energy Capital of the World."

As part of the 2026 Houston Innovation Awards, our Energy Transition Business category honors those innovative startups that are providing solutions within renewables, climatetech, clean energy, alternative materials, circular economy and more.

Five clean energy startups have been named finalists for the 2026 award. The finalists, selected by our esteemed panel of judges, range from a lower-emission steel producer to a diagnostics platform developer working to support batteries used in data centers.

Read more about these innovative businesses, their initiatives, and their inspirational founders below. The 2026 winners will be announced on InnovationMap.com in mid-November.

Capwell Services

Methane capture company Capwell Services works to eliminate vented oil and gas emissions economically for operators. According to the company, methane emissions are vented from most oil and gas facilities due to safety protocols, and operators are not able to capture the gas cost-effectively, leading operators to emit more than 14 million metric tons of methane per year in the U.S. and Canada. Founded in 2022, Capwell specializes in low and intermittent flow vents for methane capture.

The company began as a University of Pennsylvania senior design project led by CEO Andrew Lane. It has since participated in programs with Greentown Labs, the Rice Clean Energy Accelerator and the Creative Destruction Lab Energy Cohort at Texas A&M University. The company moved to Houston in 2023 and raised a pre-seed round. It deployed two commercial units this year, according to its application.

FlowCellutions

Energytech startup FlowCellutions is developing a chemistry-agnostic diagnostics platform for flow and metal-air batteries supporting data centers and critical infrastructure. The platform is designed to help reduce operating costs, prevent failures and costly downtime, and extend battery lifetime from approximately seven years to more than 30 years. It has deployed four paid pilots and plans to take insights from the programs to develop its next-gen sensor platform technology.

CEO Becca Segel founded the company in 2022. It is a member of Greentown Labs, and Segel was a 2025 Activate Fellow. The company has raised over $2 million in non-dilutive funding and received a $1.5 million NSF SBIR Fast-Track award earlier this year.

Hertha Metals

Hertha Metals produces lower-cost, lower-emission steel and high-purity iron. The company has developed a single-step process that uses natural gas as a direct reductant instead of metallurgical coal, which cuts production costs by more than 25 percent and emissions by up to 50 percent, according to the company. The same process produces high-purity iron needed for high-purity steels and rare earth magnets. The company says it aims to "re-industrialize America’s production of critical materials."

Hertha Metals was founded by CEO Laureen Meroueh in 2022 and emerged from stealth last year with more than $17 million in venture capital funding. The company closed a $133.65 million Series A this month and also broke ground on its $100M high-purity iron factory known as Chalyx in Conroe.

Mars Materials

Clean chemical manufacturing business Mars Materials is working to convert captured carbon into resources, such as carbon fiber and wastewater treatment chemicals. The company develops and produces its drop-in chemical products in Houston and uses an in-licensed process for the National Renewable Energy Lab to produce acrylonitrile, which is used to produce plastics, synthetic fibers, and rubbers.

Founded in 2019 by CEO Aaron Fitzgerald, CTO Kristian Gubsch, and vice president of operations Trey Sheridan, the company has secured over $7.2M in financing and is backed by Bill Gates’ Breakthrough Energy, Shell, Black & Veatch, and other organizations. It won in the Minority-founded Business Category in last year's Houston Innovation Awards.

Solidec

Chemical manufacturing company Solidec has developed autonomous generators that extract molecules from water and air and convert them into pure chemicals and fuels that are free of carbon emissions on-site, eliminating the need for transport, storage, and permitting. The company was founded around innovations developed by Rice University associate professor Haotian Wang.

The company was selected for the Chevron Technology Ventures’ Catalyst Program, Greentown Labs, NSF I-Corps and was part of the first cohort of the Activate Houston program. It won first place at the 2024 startup pitch competition at CERAWeek. Solidec was founded in 2023 by Wang, who serves as an advisor, CEO Ryan DuChanois, and CTO Yang Xia. It closed a $2.5 million seed round in 2025.